Dan Shelly

Dan Shelly serves as the Chief Business Development Officer at PolTREG S.A. since February 2024, while also contributing to BioStem Technologies and BioSolution Designs on their respective Scientific Advisory Board and Board of Directors. Previously, Dan held the role of Vice President of Business Development and Alliances at Prescient Therapeutics and directed global business development initiatives at PATH, focusing on health equity. Dan’s extensive experience includes positions at Albumedix and Novozymes Biopharma, where leadership in business development and contract biologics manufacturing was emphasized. Educational qualifications include an MBA in Innovation from the University of Cincinnati, a PhD in Molecular Physiology from Florida State University, and various advanced degrees from William & Mary, Lehigh University, and the University of Cincinnati College of Medicine.